FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2114483721> ?p ?o ?g. }

• W2114483721 endingPage "iv109" @default.
• W2114483721 startingPage "iv108" @default.
• W2114483721 abstract "The crude incidence of Hodgkin lymphoma (HL) in the European Union is 2.2, the mortality is 0.7/100 000 cases/year. Pathological diagnosis should be made according to the World Health Organization classification from a surgical specimen/excisional lymph node biopsy whenever possible providing sufficient material for fresh frozen and formalin-fixed samples. Classical Hodgkin lymphoma (cHL) includes nodular sclerosing, mixed cellularity, lymphocyte-rich and lymphocyte-depleted subtypes and represents about 95% of all HL cases. It is distinguished from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL), which accounts for about 5% of all HL cases. Chest X-ray and a computed tomography (CT) scan of neck, chest and abdomen are mandatory as well as bone marrow aspiration and histology. A positron emission tomography (PET) scan may be considered according to the revised response criteria. Staging laparotomy is not recommended [II, A]. Full blood cell count, erythrocyte sedimentation rate (ESR) and blood chemistry including C-reactive protein, alkaline phosphatase, lactatdehydrogenase, liver enzymes and albumin are obligatory [II–III, A]. Staging is carried out according to the Ann Arbor system in consideration of B-symptoms and the risk factors listed in Table 1. Treatment is chosen according to the categories shown in Table 1 [II–III, A].Table 1Staging according to the Ann Arbor system in consideration of B-symptoms and the risk factorsRisk factorsClinical stage (CS)IA, IB, IIAIIBIIIAIIIB, IVA, IVBNoneLLAt least three involved lymph node areasIIAAHigh ESRIIAALarge mediastinal massIAAAExtranodal diseaseIAAADefinitions: ESR, erythrocyte sedimentation rate; L, limited; I, intermediate, A, advanced.High ESR: >50 mm/h without B-symptoms, >30 mm/h with B-symptoms.Large mediastinal mass: more than one third of the horizontal chest diameter.B-symptoms: fever, night sweat, weight loss. Open table in a new tab Definitions: ESR, erythrocyte sedimentation rate; L, limited; I, intermediate, A, advanced. High ESR: >50 mm/h without B-symptoms, >30 mm/h with B-symptoms. Large mediastinal mass: more than one third of the horizontal chest diameter. B-symptoms: fever, night sweat, weight loss. Two cycles of adriamycine/bleomycin/vinblastine/dacarbazine (ABVD) are used in combination with 30 Gy involved-field radiotherapy [I, A]. In young adults, chemotherapy-only based regimens result in slightly higher relapse rates but potentially lower long-term toxicity. Four cycles of ABVD are used in combination with 30 Gy involved-field radiotherapy [I, A]. By default, patients up to age 60 years are treated with either eight cycles of ABVD or eight cycles of bleomycin/etoposide/adriamycine/cyclophospamide/vincristine/procarbazine/prednisone in escalated dosage (BEACOPPescalated) followed by 30 Gy radiotherapy of residual lymphoma larger than 1.5 cm [I–II, A]. Patients older than 60 years should undergo the ABVD chemotherapy due to higher toxicity in this age group. In first relapse, salvage regimens like the standard dexamethasone/high-dose ara-C/cisplatin (DHAP) protocol or the recently established ifosphamide/gemcitabine/vinorelbine/dexamethasone (IGEV) protocol, each followed by high-dose chemotherapy and autologous stem cell transplantation can be regarded as the treatment of choice [I, A]. Reduced intensity conditioning allogeneic stem cell transplantation (RIC-allo) should be considered in young, chemosensitive patients in good general condition relapsing after high-dose chemotherapy with autologous stem cell transplantation [II–III, B]. For palliative setting gemcitabine-based chemotherapy can achieve acceptable remission rates, a satisfying quality of life and prolonged survival. Novel single agents and/or regional radiotherapy may also be considered. Thirty Gy involved-field radiotherapy alone is the standard treatment for patients in this category [III, A]. NLPHL treatment is identical to cHL in all stages except for stage IA without risk factors. A localised NLPHL relapse should be treated with rituximab alone [III, B]. NLPHL patients with a more advanced relapse require more aggressive salvage therapy in combination with rituximab. Response evaluation should be done after four cycles and after completion of chemotherapy or chemotherapy/radiotherapy. Physical examination, laboratory analysis and CT scans are mandatory. In studies in advanced stage patients, early PET scan after two or three cycles identified poor risk patients. Based on early PET scan further therapy might be adapted to the patient's risk profile [II–III, B]. After completed treatment, positive PET scans may reveal persistent disease activity but false positive PET scan must be excluded. History, physical examination and laboratory analysis including full blood cell count, ESR and blood chemistry should be performed every 3 months for the first year, every 6 months until the fourth year and once a year thereafter [V, D]. Additional evaluation of thyroid function (thyroid-stimulating hormone) after radiation of the neck should be carried out at 1, 2 and at least 5 years [III, A]. CT scans and previously pathologic radiographic tests are performed once to confirm remission status. Afterwards they are indicated if suspicious clinical symptoms occur. Cancer screening should be conducted regularly due to the risk of secondary malignancies. Levels of evidence [I–V] and grades of recommendation [A–D] as used by the American Society of Clinical Oncology are given in square brackets. Statements without grading were considered justified standard clinical practice by the experts and the ESMO faculty." @default.
• W2114483721 created "2016-06-24" @default.
• W2114483721 creator A5046049357 @default.
• W2114483721 creator A5055488306 @default.
• W2114483721 creator A5057387418 @default.
• W2114483721 date "2009-05-01" @default.
• W2114483721 modified "2023-10-16" @default.
• W2114483721 title "Hodgkin's lymphoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up" @default.
• W2114483721 cites W2024286331 @default.
• W2114483721 cites W2034218339 @default.
• W2114483721 cites W2056977827 @default.
• W2114483721 cites W2058383365 @default.
• W2114483721 cites W2094431983 @default.
• W2114483721 cites W2109686908 @default.
• W2114483721 cites W2136962826 @default.
• W2114483721 cites W2148541783 @default.
• W2114483721 cites W2157717016 @default.
• W2114483721 cites W2329725057 @default.
• W2114483721 doi "https://doi.org/10.1093/annonc/mdp144" @default.
• W2114483721 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19454425" @default.
• W2114483721 hasPublicationYear "2009" @default.
• W2114483721 type Work @default.
• W2114483721 sameAs 2114483721 @default.
• W2114483721 citedByCount "37" @default.
• W2114483721 countsByYear W21144837212012 @default.
• W2114483721 countsByYear W21144837212013 @default.
• W2114483721 countsByYear W21144837212014 @default.
• W2114483721 countsByYear W21144837212015 @default.
• W2114483721 countsByYear W21144837212016 @default.
• W2114483721 countsByYear W21144837212018 @default.
• W2114483721 countsByYear W21144837212020 @default.
• W2114483721 countsByYear W21144837212022 @default.
• W2114483721 crossrefType "journal-article" @default.
• W2114483721 hasAuthorship W2114483721A5046049357 @default.
• W2114483721 hasAuthorship W2114483721A5055488306 @default.
• W2114483721 hasAuthorship W2114483721A5057387418 @default.
• W2114483721 hasBestOaLocation W21144837211 @default.
• W2114483721 hasConcept C126322002 @default.
• W2114483721 hasConcept C126838900 @default.
• W2114483721 hasConcept C146357865 @default.
• W2114483721 hasConcept C151730666 @default.
• W2114483721 hasConcept C2775934546 @default.
• W2114483721 hasConcept C2778143017 @default.
• W2114483721 hasConcept C2778818763 @default.
• W2114483721 hasConcept C2779338263 @default.
• W2114483721 hasConcept C2779714933 @default.
• W2114483721 hasConcept C2780007613 @default.
• W2114483721 hasConcept C2780778865 @default.
• W2114483721 hasConcept C2780849966 @default.
• W2114483721 hasConcept C2989005 @default.
• W2114483721 hasConcept C71924100 @default.
• W2114483721 hasConcept C86803240 @default.
• W2114483721 hasConceptScore W2114483721C126322002 @default.
• W2114483721 hasConceptScore W2114483721C126838900 @default.
• W2114483721 hasConceptScore W2114483721C146357865 @default.
• W2114483721 hasConceptScore W2114483721C151730666 @default.
• W2114483721 hasConceptScore W2114483721C2775934546 @default.
• W2114483721 hasConceptScore W2114483721C2778143017 @default.
• W2114483721 hasConceptScore W2114483721C2778818763 @default.
• W2114483721 hasConceptScore W2114483721C2779338263 @default.
• W2114483721 hasConceptScore W2114483721C2779714933 @default.
• W2114483721 hasConceptScore W2114483721C2780007613 @default.
• W2114483721 hasConceptScore W2114483721C2780778865 @default.
• W2114483721 hasConceptScore W2114483721C2780849966 @default.
• W2114483721 hasConceptScore W2114483721C2989005 @default.
• W2114483721 hasConceptScore W2114483721C71924100 @default.
• W2114483721 hasConceptScore W2114483721C86803240 @default.
• W2114483721 hasLocation W21144837211 @default.
• W2114483721 hasLocation W21144837212 @default.
• W2114483721 hasOpenAccess W2114483721 @default.
• W2114483721 hasPrimaryLocation W21144837211 @default.
• W2114483721 hasRelatedWork W2005258889 @default.
• W2114483721 hasRelatedWork W2055328664 @default.
• W2114483721 hasRelatedWork W2120426115 @default.
• W2114483721 hasRelatedWork W2153478466 @default.
• W2114483721 hasRelatedWork W226843782 @default.
• W2114483721 hasRelatedWork W2281311037 @default.
• W2114483721 hasRelatedWork W2330939570 @default.
• W2114483721 hasRelatedWork W2373000095 @default.
• W2114483721 hasRelatedWork W2906035546 @default.
• W2114483721 hasRelatedWork W2984415333 @default.
• W2114483721 hasVolume "20" @default.
• W2114483721 isParatext "false" @default.
• W2114483721 isRetracted "false" @default.
• W2114483721 magId "2114483721" @default.
• W2114483721 workType "article" @default.